Adial Pharmaceuticals, Inc.
ADIL
NASDAQ·Healthcare·Biotechnology·Mkt cap $10.5M
$3.98
▼ -8.51%
P/E
—
Mkt Cap
$10.5M
52-Wk Range
$1.31–$10.75
52-Week Range
$1.31 - $10.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 59.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary selective serotonin-3 antagonist technology
- Advanced Phase III clinical trial status for AD04
- Focused pipeline addressing high-incidence, underserved conditions
- Specialized expertise in addiction and pain management therapeutics
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Successful Phase III trial completion and FDA approval potential for AD04
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+36.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ADIL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 18, 2026
AUG 14, 2026
Reported EPS of -$11.25 vs -$1.03 consensus (-989.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-989.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Alliance Global Partners · Aug 3, 2026
vs Industry
How ADIL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related